{"id":743850,"date":"2013-01-11T07:39:00","date_gmt":"2013-01-11T07:39:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-next-steps-for-tredaptive-extended-release-niacin-laropiprant\/"},"modified":"2023-03-22T00:04:42","modified_gmt":"2023-03-22T04:04:42","slug":"merck-provides-update-on-next-steps-for-tredaptive-extended-release-niacin-laropiprant","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-next-steps-for-tredaptive-extended-release-niacin-laropiprant\/","title":{"rendered":"Merck Provides Update on Next Steps for TREDAPTIVE\u2122 (extended-release niacin\/laropiprant)"},"content":{"rendered":"<p>\n      Merck (NYSE: MRK), known as MSD outside of the United States and Canada,<br \/>\n      today announced the company is taking steps to suspend the availability<br \/>\n      of TREDAPTIVE<sup>\u2122<\/sup> (extended-release niacin\/laropiprant) tablets<br \/>\n      worldwide. TREDAPTIVE is not approved for use in the United States.\n    <\/p>\n<p>\n      Merck is taking these steps based on the current understanding of the<br \/>\n      preliminary data from the HPS2-THRIVE (<b>H<\/b>eart <b>P<\/b>rotection <b>S<\/b>tudy<br \/>\n      2-<b>T<\/b>reatment of <b>H<\/b>DL to <b>R<\/b>educe the <b>I<\/b>ncidence<br \/>\n      of <b>V<\/b>ascular <b>E<\/b>vents) study, and in consultation with<br \/>\n      regulatory authorities. As previously reported by Merck (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fpress-release%2Fprescription-medicine-news%2Fmerck-announces-hps2-thrive-study-tredaptive-extended-relea&#038;esheet=50528718&#038;lan=en-US&#038;anchor=Dec.+20%2C+2012+news+release&#038;index=1&#038;md5=51cdfe265c190323dc0a048d42c5e089\">Dec.<br \/>\n      20, 2012 news release<\/a>), HPS2-THRIVE did not achieve its primary<br \/>\n      endpoint of reduction of major vascular events, and there was a<br \/>\n      statistically significant increase in the incidence of some types of<br \/>\n      non-fatal serious adverse events in the group that received TREDAPTIVE<br \/>\n      compared to statin therapy. The decision to suspend availability of the<br \/>\n      medicine is aligned with the recommendation of the European Medicine<br \/>\n      Agency\u2019s Pharmacovigilance Risk Assessment Committee (PRAC) based on the<br \/>\n      trial\u2019s results.\n    <\/p>\n<p>\n      In countries where the medicine is currently available, Merck has begun<br \/>\n      informing regulatory agencies of the company\u2019s decision. Merck is<br \/>\n      working with these agencies to develop communications for health care<br \/>\n      providers and to suspend the availability of TREDAPTIVE, with the timing<br \/>\n      to be based on individual country regulations and processes.\n    <\/p>\n<p>\n      Merck is recommending that physicians stop prescribing TREDAPTIVE. Merck<br \/>\n      is also recommending that physicians review treatment plans for patients<br \/>\n      taking TREDAPTIVE in a timely manner to discontinue TREDAPTIVE and<br \/>\n      consider other changes in therapy to achieve their dyslipidemia<br \/>\n      management goals. In the meantime, Merck encourages patients with<br \/>\n      questions to speak with their health care provider, and to not<br \/>\n      discontinue therapy without first speaking with their physician.\n    <\/p>\n<p>\n      \u201cPatients currently taking TREDAPTIVE are our priority, and we are<br \/>\n      committed to continue to work with regulatory agencies around the world<br \/>\n      to ensure that physicians have appropriate information as we take steps<br \/>\n      to suspend the availability of TREDAPTIVE,\u201d said Michael Rosenblatt,<br \/>\n      M.D., Chief Medical Officer, Merck.\n    <\/p>\n<p>\n      <b>About the HPS 2-THRIVE Study<\/b>\n    <\/p>\n<p>\n      HPS2-THRIVE was independently conducted by the Clinical Trial Service<br \/>\n      Unit at Oxford University and funded by Merck. With the agreement of the<br \/>\n      independent research team at Oxford University, Merck is sharing results<br \/>\n      from the study with regulatory agencies. The investigators are<br \/>\n      conducting additional analyses to further understand the results. They<br \/>\n      anticipate reporting the detailed study results in the first quarter of<br \/>\n      2013.\n    <\/p>\n<p>\n      The study enrolled 25,673 patients considered to be at high risk for<br \/>\n      cardiovascular events. Of those enrolled, 14,741 were from Europe (the<br \/>\n      United Kingdom and Scandinavia) and 10,932 were from China. Patients in<br \/>\n      the study were followed for a median of 3.9 years. HPS2-THRIVE compared<br \/>\n      extended release niacin and laropiprant plus statin therapy versus<br \/>\n      statin therapy. It was not designed to assess directly the separate<br \/>\n      effects of either extended-release niacin or laropiprant.\n    <\/p>\n<p>\n      In the study, adding the combination of extended-release niacin and<br \/>\n      laropiprant to statin therapy did not significantly further reduce the<br \/>\n      risk of the combination of coronary deaths, nonfatal heart attacks,<br \/>\n      strokes or revascularizations compared to statin therapy. In addition,<br \/>\n      there was a statistically significant increase in the incidence of some<br \/>\n      types of non-fatal serious adverse events in the group that received<br \/>\n      extended-release niacin\/laropiprant.\n    <\/p>\n<p>\n      Preliminary analyses suggest that the adverse events fall within the<br \/>\n      following broad categories: blood and lymphatic, gastrointestinal,<br \/>\n      infections, metabolism, musculoskeletal, respiratory and skin.<br \/>\n      Additional analyses are ongoing to understand the adverse events within<br \/>\n      these categories.\n    <\/p>\n<p>\n      TREDAPTIVE has been approved in approximately 70 countries, including in<br \/>\n      Europe, and is sold in approximately 40 countries. TREDAPTIVE is also<br \/>\n      sold under the brand names PELZONT in Italy and TREVACLYN in Italy and<br \/>\n      Portugal and CORDAPTIVE in other markets around the world. Sales through<br \/>\n      the first three quarters of 2012 were approximately $13 million.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside of the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50528718&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=2&#038;md5=b4df01047c6f419d3ddd867282349e30\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on Twitter, Facebook and YouTube.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. If underlying<br \/>\n      assumptions prove inaccurate or risks or uncertainties materialize,<br \/>\n      actual results may differ materially from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2011 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50528718&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=3&#038;md5=52e26d95135801141d431c27ec53ce9f\">www.sec.gov<\/a>).\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20130111005292r1&#038;sid=sfsite1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 908-423-5042<br \/>or<br \/>Skip        Irvine, 267-305-5397<br \/>or<br \/>Investors:<br \/>Carol Ferguson,        908-423-4465<br \/>or<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the company is taking steps to suspend the availability of TREDAPTIVE \u2122 (extended-release niacin\/laropiprant) tablets worldwide. TREDAPTIVE is not approved for use in the United States. Merck is taking these steps based on the current understanding of the preliminary data from the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study, and in consultation with regulatory authorities. As previously reported by Merck (Dec. 20, 2012 news release), HPS2-THRIVE did not achieve its primary endpoint of reduction of major vascular events, and there was a statistically significant increase in the incidence of some types of non-fatal serious adverse events in the group that received TREDAPTIVE compared to statin therapy. The decision to suspend availability of the medicine is aligned with the recommendation of the European Medicine Agency\u2019s Pharmacovigilance<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[289,56],"class_list":["post-743850","news_item","type-news_item","status-publish","hentry","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Provides Update on Next Steps for TREDAPTIVE\u2122 (extended-release niacin\/laropiprant) - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-next-steps-for-tredaptive-extended-release-niacin-laropiprant\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Provides Update on Next Steps for TREDAPTIVE\u2122 (extended-release niacin\/laropiprant) - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the company is taking steps to suspend the availability of TREDAPTIVE \u2122 (extended-release niacin\/laropiprant) tablets worldwide. TREDAPTIVE is not approved for use in the United States. Merck is taking these steps based on the current understanding of the preliminary data from the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study, and in consultation with regulatory authorities. As previously reported by Merck (Dec. 20, 2012 news release), HPS2-THRIVE did not achieve its primary endpoint of reduction of major vascular events, and there was a statistically significant increase in the incidence of some types of non-fatal serious adverse events in the group that received TREDAPTIVE compared to statin therapy. The decision to suspend availability of the medicine is aligned with the recommendation of the European Medicine Agency\u2019s Pharmacovigilance\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-next-steps-for-tredaptive-extended-release-niacin-laropiprant\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:42+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130111005292r1&sid=sfsite1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-next-steps-for-tredaptive-extended-release-niacin-laropiprant\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-next-steps-for-tredaptive-extended-release-niacin-laropiprant\\\/\",\"name\":\"Merck Provides Update on Next Steps for TREDAPTIVE\u2122 (extended-release niacin\\\/laropiprant) - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-next-steps-for-tredaptive-extended-release-niacin-laropiprant\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-next-steps-for-tredaptive-extended-release-niacin-laropiprant\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130111005292r1&sid=sfsite1&distro=nx\",\"datePublished\":\"2013-01-11T07:39:00+00:00\",\"dateModified\":\"2023-03-22T04:04:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-next-steps-for-tredaptive-extended-release-niacin-laropiprant\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-next-steps-for-tredaptive-extended-release-niacin-laropiprant\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-next-steps-for-tredaptive-extended-release-niacin-laropiprant\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130111005292r1&sid=sfsite1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130111005292r1&sid=sfsite1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-next-steps-for-tredaptive-extended-release-niacin-laropiprant\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Provides Update on Next Steps for TREDAPTIVE\u2122 (extended-release niacin\\\/laropiprant)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Provides Update on Next Steps for TREDAPTIVE\u2122 (extended-release niacin\/laropiprant) - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-next-steps-for-tredaptive-extended-release-niacin-laropiprant\/","og_locale":"en_US","og_type":"article","og_title":"Merck Provides Update on Next Steps for TREDAPTIVE\u2122 (extended-release niacin\/laropiprant) - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the company is taking steps to suspend the availability of TREDAPTIVE \u2122 (extended-release niacin\/laropiprant) tablets worldwide. TREDAPTIVE is not approved for use in the United States. Merck is taking these steps based on the current understanding of the preliminary data from the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study, and in consultation with regulatory authorities. As previously reported by Merck (Dec. 20, 2012 news release), HPS2-THRIVE did not achieve its primary endpoint of reduction of major vascular events, and there was a statistically significant increase in the incidence of some types of non-fatal serious adverse events in the group that received TREDAPTIVE compared to statin therapy. The decision to suspend availability of the medicine is aligned with the recommendation of the European Medicine Agency\u2019s Pharmacovigilance","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-next-steps-for-tredaptive-extended-release-niacin-laropiprant\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:42+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130111005292r1&sid=sfsite1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-next-steps-for-tredaptive-extended-release-niacin-laropiprant\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-next-steps-for-tredaptive-extended-release-niacin-laropiprant\/","name":"Merck Provides Update on Next Steps for TREDAPTIVE\u2122 (extended-release niacin\/laropiprant) - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-next-steps-for-tredaptive-extended-release-niacin-laropiprant\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-next-steps-for-tredaptive-extended-release-niacin-laropiprant\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130111005292r1&sid=sfsite1&distro=nx","datePublished":"2013-01-11T07:39:00+00:00","dateModified":"2023-03-22T04:04:42+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-next-steps-for-tredaptive-extended-release-niacin-laropiprant\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-next-steps-for-tredaptive-extended-release-niacin-laropiprant\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-next-steps-for-tredaptive-extended-release-niacin-laropiprant\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130111005292r1&sid=sfsite1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130111005292r1&sid=sfsite1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-next-steps-for-tredaptive-extended-release-niacin-laropiprant\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Provides Update on Next Steps for TREDAPTIVE\u2122 (extended-release niacin\/laropiprant)"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"2e9b4a57-bc85-4a2f-8c08-f8a7b93bed21","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743850","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743850\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=743850"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=743850"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}